Salspera Files IPO to Fund Phase 3 Trial of Saltikva Bacterial Immunotherapy for Pancreatic Cancer
核心洞察
Salspera (搜索) filed for a Nasdaq IPO to raise $50-85 million to fund Phase 3 development of Saltikva, a genetically engineered Salmonella typhimurium bacterium that delivers IL-2 directly to tumors.
Phase 2 results showed Saltikva combined with FOLFIRINOX achieved median overall survival of 20.3 months versus 11.5 months in historical controls for metastatic pancreatic cancer (搜索).
The live bacterial immunotherapy has received FDA Fast Track designation and Orphan Drug status for pancreatic cancer (搜索), targeting a disease with limited therapeutic progress.
Salspera (搜索), a clinical-stage biotechnology company developing live bacterial immunotherapies, has filed for an initial public offering on the Nasdaq Stock Market under the ticker "TKVA" to advance its lead candidate Saltikva through pivotal Phase 3 trials. The Cambridge, Massachusetts-based company aims to raise $50-85 million through the offering, with Kingswood Capital Partners (搜索) serving as sole book-running manager.
The IPO proceeds will primarily fund a Phase 3 trial of Saltikva in metastatic pancreatic cancer (搜索), along with Phase 2 programs in osteosarcoma (搜索) and colorectal cancer (搜索), and general corporate purposes.
Novel Bacterial Immunotherapy Platform
Saltikva represents a first-in-class "live biopharmaceutical" - an attenuated Salmonella typhimurium bacterium genetically engineered to carry the human interleukin-2 (IL-2) gene. The therapy is administered orally, allowing the non-pathogenic bacteria to selectively colonize tumor tissues and locally secrete IL-2 within the tumor microenvironment.
This approach leverages bacteria's intrinsic tumor-homing ability to deliver IL-2 directly to cancer sites, where it expands populations of natural killer (NK) cells and CD8+ T-cells capable of destroying cancer cells. By concentrating immune activation within tumors, Saltikva is designed to provoke anti-tumor immune responses while limiting systemic exposure and toxicity.
Promising Phase 2 Results in Pancreatic Cancer
Salspera (搜索) recently completed a Phase 2 trial evaluating Saltikva in combination with FOLFIRINOX chemotherapy for stage IV pancreatic ductal adenocarcinoma. The study demonstrated significant improvements in patient outcomes compared to historical controls treated with chemotherapy alone.
In the compliant cohort, patients receiving Saltikva with FOLFIRINOX achieved a median progression-free survival of approximately 15 months compared to 5.8 months in historical controls. More notably, median overall survival reached 20.3 months versus 11.5 months in controls - representing a substantial improvement for a disease with historically poor prognosis.
The trial reported a 70% overall response rate with partial responses achieved in 70% of patients. Importantly, no serious adverse events were attributable to Saltikva, with toxicity profiles driven by the chemotherapy component, indicating a favorable safety profile for the bacterial therapy.
Regulatory Recognition and Market Opportunity
Saltikva has received FDA Fast Track designation for pancreatic cancer (搜索), as well as Orphan Drug Designation for both pancreatic cancer and osteosarcoma (搜索). These designations underscore the therapy's potential to address significant unmet medical needs in difficult-to-treat cancers.
The pancreatic cancer (搜索) market represents a substantial opportunity, with approximately 67,440 new U.S. cases expected in 2025 and roughly 500,000 cases globally each year. Limited improvement in pancreatic cancer outcomes over the last 15 years highlights the urgent need for new therapeutic approaches.
Leadership and Development Strategy
The company is led by co-founder and CEO Eddie Moradian, PhD, who brings three decades of experience founding and co-founding biotech firms, and co-founder and Chief Medical Officer Daniel Saltzman, MD, PhD, a Professor of Surgery and Pediatrics who has pioneered bacterial-based cancer therapy with over 160 publications.
Salspera (搜索)'s business model includes potential partnerships for late-stage development and commercialization across oncology markets. The company operates from headquarters in Cambridge, Massachusetts, with research and manufacturing laboratories in Oakdale, Minnesota.
Financial Position and Future Plans
As a pre-revenue company, Salspera (搜索) reported a net loss of $1,401,982 for 2024 and $9,399,963 for the nine months ended September 30, 2025. The planned IPO represents a critical funding milestone to support the transition from Phase 2 to Phase 3 development.
Beyond pancreatic cancer (搜索), Salspera (搜索) plans to advance Saltikva in Phase 2/3 development for osteosarcoma (搜索) and metastatic colorectal cancer (搜索), potentially expanding the therapy's application across multiple solid tumor types. Clinical work has been conducted in North America, with the Phase 2 trial site in Montreal, Canada, and plans for U.S.-led Phase 3 trials with participation from the EU, Australia, and Israel.